徐建青

人才队伍

全聘课题组长

徐建青
研究员，博士生导师，复旦大学生物医学研究院免疫治疗课题组PI
邮箱：xujianqing@fudan.edu.cn
实验室主页：http://www.hiv.fudan.edu.cn
艾滋病免疫抑制疗法和根治策略研究；获批经费2185万元(子课题组组长)

工作经历

研究员，复旦大学，生物医学研究院（2007.12-今）
双聘教授，复旦大学附属中山医院（2021-今）
双聘教授，院长，上海市公共卫生临床中心，转化医学研究院（2007-今）
副研究员，中国疾病预防控制中心艾滋病预防控制中心（2004-2007）
Research assistant professor，Department of Microbiology and Immunology，Georgetown University (2001-2004)
Senior research associate，Research Institute for Genetic and Human Therapy affiliated to Georgetown University (2001-2004)
Postdoctoral research fellow，Research Institute for Genetic and Human Therapy affiliated to Georgetown University (1997-2001)

教育经历

医学博士，中国医学科学院&中国协和医科大学（1994-1997）
医学硕士，中国医科大学（1991-1994）
医学学士，中国医科大学（1986-1991）

所获人才项目

2015，上海市医学领军人才
2016，上海市领军人才

所获奖项

2004-2006，中国疾病预防控制中心艾滋病预防控制中心“先进工作者”（连续三年）
2008，上海市公共卫生优秀学科带头人
2009，上海市公共卫生临床中心“优秀本科生课程授课教师”
2010，南开大学艾滋病研究中心学术顾问
2011，上海医学科技奖三等奖（第二完成人）
2011，上海市优秀学术带头人
2011，“新一轮上海市卫生系统优秀学科带头人培养计划”培养对象
2011，上海市公共卫生临床中心“优秀团队和人才奖励计划”铜奖
2012，黑龙江高校“感染与免疫”科技创新团队特聘专家
2013，上海市科学技术三等奖1项（甲型流感的诊断、救治与预防应对的策略研究与应用，第三）

研究方向

徐建青教授主要从事感染免疫学与免疫治疗学研究。先后主持国家“十五”科技攻关项目，国家“十一五”、“十二五”与“十三五”重大传染病科技专项项目，重点研发计划项目、美国NIH项目，国家自然科学基金重大研究计划、国家自然科学基金重点及国际合作项目；在Nature、Science、Cell、Nature Immunology、Nature Microbiology、PNAS、Cell Discovery、Nat Commun、EClinicalMedicine、Clin Infect Dis、Neurology、Biomaterials等杂志发表SCI论文240余篇；近5年发表116篇，其中以第一/通讯（共同）作者共发表76篇；申报专利80余项，授权30余项。
1.感染免疫保护与致病机制研究：利用急性与慢性感染模型（流感、HIV、LCMV），观察与解析机体的免疫保护、T细胞的发育、分化与损伤机制以及T细胞与固有免疫应答的相互作用；2.研发抗感染的免疫治疗、药物与疫苗：在国际上率先提出不同免疫原序贯免疫策略、以优势活化针对病毒保守区域的疫苗策略，设计新型疫苗；同时，根据揭示的免疫学机制，研发新的免疫治疗策略与抗体药物，已申报多项专利；3.研发新型肿瘤免疫治疗技术：开展iNKT治疗晚期实体瘤的临床研究；同时，进一步研发肿瘤微环境激活的CAR-T技术（Tumor Microenvironment Activating CAR-T, TMA-CAR-T），该技术利用肿瘤微环境敏感技术，使得CAR-T仅在肿瘤微环境中杀伤肿瘤细胞，在肿瘤微环境以外场所不能够识别任何抗原，从而避免了非特异杀伤。

招生专业

医学系统生物学

代表论文

*indicated the corresponding author. More than 240 scientific papers have been published in total. More published papers can be viewed on Prof Xu’s Research Gate profile (https://www.researchgate.net/profile/Jianqing-Xu-2).

1.Jia X, Crawford JC, Gebregzabher D, Monson EA, Mettelman RC, Wan Y, Ren Y, Chou J, Novak T, McQuilten HA, Clarke M, Bachem A, Foo IJ, Fritzlar S, Montoya JC, Trenerry AM, Nie S, Leeming MG, Nguyen THO, Kedzierski L, Littler D, Kueh A, Cardamone T, Wong C, Hensen L, Cabug A1, Gómez Laguna J, Agrawal M, Flerlage T, Boyd DF, Van de Velde LE, Habel JR, Loh L, Koay HF, van de Sandt C, Konstantinov IE, Berzins SP, Flanagan KL, Wakim LM, Herold MJ, Green AM, Smallwood HS, Rossjohn J, Thwaites RS, Chiu C, Scott NE, Mackenzie JM, Bedoui S, Reading PC, Londrigan SL, Helbig KJ, Randolph AG, Thomas PG, Xu J, Wang Z, Chua and Kedzierska K. High expression of oleoyl-ACP-hydrolase underpins life-threatening respiratory viral diseases. Cell. 2024 (in press).

2.Mao Y, Liao Q, Zhu Y, Bi M, Zou J, Zheng N, Zhu L, Zhao C, Liu Q, Liu L, Chen J, Gu L, Liu Z, Pan X, Xue Y, Feng M, Ying T, Zhou P, Wu Z, Xiao J, Zhang R*, Leng J*, Sun Y*, Zhang X*, Xu J*. Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study. Cell Discov. 2024 May 14;10(1):49. doi: 10.1038/s41421-024-00658-z.

3.Zhou P, Qiu T, Wang X, Yang X, Shi H, Zhu C, Dai W, Xing M, Zhang X, Xu J*, Zhou D*. One HA stalk topping multiple heads as a novel influenza vaccine. Emerg Microbes Infect. 2024 Dec;13(1):2290838. doi: 10.1080/22221751.2023.2290838.

4.Xing M, Hu G, Wang X, Wang Y, He F, Dai W, Wang X, Niu Y, Liu J, Liu H, Zhang X, Xu J*, Cai Q*, Zhou D*. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza. NPJ Vaccines. 2024 Mar 21;9(1):64. doi: 10.1038/s41541-024-00857-5.

5.Xingyue Wu, Yao Chen, Kangli Cao, Yao Shen, Xueling Wu, Yilin Yang, Zhongshu Kuang, Qingrun Li, Zhenzhen Lu, Yichen Jia, Mian Shao, Guorong Gu, Xiangwei Wang, Ye Yao, Ying Wang, Shaodie Chen, Zhigao Yu, Wei Wei, Longfei Ding, Lulu Lan, Tianwen Gu, Xiangyu Long, Jian Sun, Lingyu Xing, Jiayuan Shen, Yi Han, Yue Luo, Sucheng Mu, Mengna Lin, Xiaoyan Zhang, Rong Zeng, Jianqing Xu*, Guoping Zhao*, Lihong Huang*, Zhenju Song*, Reduced clinical severity during 2022 Shanghai Spring epidemic of SARS-CoV-2 omicron BA.2 variant infection - An integrated account of virus pathogenicity and vaccination effectiveness, National Science Review, 2024;, nwae011, https://doi.org/10.1093/nsr/nwae011

6.Zhou P, Qiu T, Wang X, Yang X, Shi H, Zhu C, Dai W, Xing M, Zhang X, Xu J*, Zhou D*. One HA stalk topping multiple heads as a novel influenza vaccine. Emerg Microbes Infect. 2023 Dec 4:2290838. doi: 10.1080/22221751.2023.2290838.

7.Zhang L, Zhang A, Zhu X, Tian X, Guo J, He Q, Zhu L, Yuan S, Zhao C*, Zhang X*, Xu J*. CD160 Signaling Is Essential for CD8+ T Cell Memory Formation via Upregulation of 4-1BB. J Immunol. 2023 Nov 1;211(9):1367-1375. doi: 10.4049/jimmunol.2200792.

8.Gao R, Li A, Li S, Li X, Zhang S, Zhang X*, Xu J*. Induced regulatory T cells modified by knocking down T-bet in combination with ectopic expression of inhibitory cytokines effectively protect graft-versus-host disease. Am J Transplant. 2023 Jul;23(7):946-956. doi: 10.1016/j.ajt.2023.04.017.

9.Qibin Liao#, Huan He#, Zhuoqun Liu#, Cuisong Zhu, Meiqi Feng, Lang Jiang, Xiangqing Ding, Xiaoyan Zhang*, Jianqing Xu*. Rapid generation of a mouse model for evaluating on-target normal tissue toxicity of human CAR-T cells using replication-defective recombinant adenovirus. Journal of Advanced Research. 2023 May; 47:163-171. doi: 10.1016/j.jare.2022.08.008.

10.Lin M, Cao K, Xu F, Wu X, Shen Y, Lu S, Kuang Z, Ding H, Yuan S, Shao M, Gu G, Xing L, Gu T, Chen S, Sun J, Zhu J, Zhang X, Yang Y, Zhao G*, Huang L*, Xu J*, Song Z*. A follow-up study on the recovery and reinfection of Omicron COVID-19 patients in Shanghai, China. Emerg Microbes Infect. 2023 Dec;12(2):2261559. doi: 10.1080/22221751.2023.2261559.

11.Xiaoyu Sun, Chunyan Yi, Yuanfei Zhu, Longfei Ding, Shuai Xia, Xingchen Chen, Mu Liu, Chenjian Gu, Xiao Lu, Yadong Fu, Shuangfeng Chen, Tianlong Zhang,Yaguang Zhang, Zhuo Yang, Liyan Ma, Wangpeng Gu, Gaowei Hu, Shujuan Du, Renhong Yan, Weihui Fu, Songhua Yuan, Chenli Qiu, Chen Zhao, Xiaoyan Zhang, Yonghui He, Aidong Qu, Xu Zhou, Xiuling Li, Gary Wong, Qiang Deng, Qiang Zhou, Hongzhou Lu, Zhiyang Ling*, Jianping Ding*, Lu Lu*, Xu J*, Youhua Xie* and Bing Sun* . Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nature Microbiology, 2022, 7(7):1063-1074. doi: 10.1038/s41564-022-01155-3.

12.Wang Y, Tian Q, Hao Y, Yao W, Lu J, Chen C, Chen X, Lin Y, Huang Q, Xu L, Hu J, Lei S, Wei Z, Luo Y, Li Z, Hu L, Tang J, Wu Q, Zhou X, Wu Y, Yin Z*, Xu J*, Ye L*. The kinase complex mTORC2 promotes the longevity of virus-specific memory CD4+ T cells by preventing ferroptosis. Nat Immunol. 2022 Feb;23(2):303-317. doi: 10.1038/s41590-021-01090-1.

13.Cheng X, Wang J, Qiu C, Jin Y, Xia B, Qin R, Hu H, Yan J, Zhang X*, Xu J*. Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma: Preliminary results of a phase I/II clinical trial. Clin Immunol. 2022 Mar 30;238:108992. doi: 10.1016/j.clim.2022.108992.

14.Cao K, Wang X, Peng H, Ding L, Wang X, Hu Y, Dong L, Yang T, Hong X, Xing M, Li D, Zhu C, He X, Zhao C, Zhao P, Zhou D*, Zhang X*, Xu J*. A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice. J Virol. 2022 Feb 23;96(4): e0157821. doi: 10.1128/JVI.01578-21.

15.Li W, Yang S, Xu P, Zhang D, Tong Y, Chen L, Jia B, Li A, Lian C, Ru D, Zhang B, Liu M, Chen C, Fu W, Yuan S, Gu C, Wang L, Li W, Liang Y, Yang Z, Ren X, Wang S, Zhang X, Song Y, Xie Y, Lu H, Xu J*, Wang H*, Yu W*. SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network. EBioMedicine. 2022 Feb;76:103861. doi: 10.1016/j.ebiom.2022.103861.

16.Wang J, Zhang R, Ding X, Jin Y, Qin R, Xia B, Liao Q, Hu H, Song W, Wang Z, Zhang X, Xu J*. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient. Immunotherapy. 2022 Apr 20. doi: 10.2217/imt-2021-0247.

17.Chen J, Liu J, Chen Z, Peng H, Zhu C, Feng D, Zhang S, Zhao P, Zhang X, Xu J*. Angiotensin-Converting Enzyme 2 Potentiates SARS-CoV-2 Infection by Antagonizing Type I Interferon Induction and Its Down-Stream Signaling Pathway. mSphere. 2022 Aug 31;7(4):e0021122. doi: 10.1128/msphere.00211-22. Epub 2022 Jul 12.

18.Wang Y, Qian G, Zhu L, Zhao Z, Liu Y, Han W, Zhang X, Zhang Y, Xiong T, Zeng H, Yu X, Yu X, Zhang X, Xu J*, Zou Q*, Yan D*. HIV-1 Vif suppresses antiviral immunity by targeting STING. Cell Mol Immunol. 2022 Jan;19(1):108-121. doi: 10.1038/s41423-021-00802-9.

19.Xiangchuan He, Longfei Ding, Kangli Cao, Haoran Peng, Chenjian Gu, Yutang Li, Duoduo Li, Lanlan Dong, Xiujing Hong, Xiangwei Wang, Meilan Fu, Chenli Qiu, Cuisong Zhu, Ziling Zhang, Shu Song, Chenguang Wang, Zhengfan Jiang, Youhua Xie, Zhongtian Qi, Chen Zhao, Ping Zhao, Xiaoyan Zhang, Xu J*. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. Emerg Microbes Infect. 2021;10(1):1555-1573.

20.Jian Chen, Jun Fan, Zhilu Chen, Miaomiao Zhang, Haoran Peng, Jian Liu, Longfei Ding, Mingbin Liu, Chen Zhao, Ping Zhao *, Shuye Zhang,*, Xiaoyan Zhang*, Xu J*. Nonmuscle myosin heavy chain IIA facilitate SARS-CoV-2 infection in human pulmonary cells. PNAS, 2021, 118: No. 00 e2111011118. https://doi.org/10.1073/pnas.2111011118.